Leap's sirexatamab shows statistically significant PFS/OS benefit in DKK1-high CRC at ESMO 2025

CYPHERPUNK TECHNOLOGIES INC.

In DKK1-high (upper median, n=88): mPFS 9.03 vs 7.06 mo (HR 0.61, p=0.0255); mOS not reached vs 14.39 mo (HR 0.42, p=0.0118).
In DKK1-high (upper quartile, n=44): mPFS 9.36 vs 5.88 mo (HR 0.46, p=0.017); mOS not reached vs 9.66 mo (HR 0.17, p<0.001).
Full ITT (n=188): mPFS 9.2 vs 8.3 mo (HR 0.84, p=0.171); ORR 35.1% vs 26.6%.
Sirexatamab well tolerated; TEAE profile similar between arms.
Leap plans to engage regulators on registrational path for sirexatamab in CRC; supported by recent financing.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.